Wellgistics Health Inc. Reports $18.65 Million Revenue in H1 2025, Slight Increase from $18.25 Million in H1 2024

Reuters

08/20

<a href="https://laohu8.com/S/WGRX">Wellgistics Health Inc.</a> Reports $18.65 Million Revenue in H1 2025, Slight Increase from $18.25 Million in H1 2024

Wellgistics Health Inc. (NASDAQ:WGRX) reported financial results for the second fiscal quarter ending June 30, 2025. The company's revenue on a pro forma basis for the first half of 2025 stood at $18.65 million, compared to $18.25 million in the first half of 2024, reflecting a slight increase. Since its initial public offering in February 2025, Wellgistics Health has consolidated its operations, streamlined staffing, and upgraded its ERP system to support growth. The company is also expanding its direct-to-patient programs, leveraging a network of over 6,500 independent pharmacies and 200 manufacturers to enhance its reach in therapeutic areas such as diabetes, weight loss, chronic pain, sleep disorders, and men's and women's health. The CEO emphasized the company's focus on accelerating growth through strategic funding and expanding access via its direct-to-patient delivery models.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wellgistics Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1063183) on August 20, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2560106443"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2560106443\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2560106443?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-20 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560106443","market":"fut","top_or_hot":-1,"title":"Wellgistics Health Inc. Reports $18.65 Million Revenue in H1 2025, Slight Increase from $18.25 Million in H1 2024","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/WGRX\">Wellgistics Health Inc.</a> Reports $18.65 Million Revenue in H1 2025, Slight Increase from $18.25 Million in H1 2024\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Wellgistics Health Inc. (NASDAQ:WGRX) reported financial results for the second fiscal quarter ending June 30, 2025. The company's revenue on a pro forma basis for the first half of 2025 stood at $18.65 million, compared to $18.25 million in the first half of 2024, reflecting a slight increase. Since its initial public offering in February 2025, Wellgistics Health has consolidated its operations, streamlined staffing, and upgraded its ERP system to support growth. The company is also expanding its direct-to-patient programs, leveraging a network of over 6,500 independent pharmacies and 200 manufacturers to enhance its reach in therapeutic areas such as diabetes, weight loss, chronic pain, sleep disorders, and men's and women's health. The CEO emphasized the company's focus on accelerating growth through strategic funding and expanding access via its direct-to-patient delivery models.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wellgistics Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1063183) on August 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wellgistics Health Inc. Reports $18.65 Million Revenue in H1 2025, Slight Increase from $18.25 Million in H1 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWellgistics Health Inc. Reports $18.65 Million Revenue in H1 2025, Slight Increase from $18.25 Million in H1 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-20 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/WGRX\">Wellgistics Health Inc.</a> Reports $18.65 Million Revenue in H1 2025, Slight Increase from $18.25 Million in H1 2024\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Wellgistics Health Inc. (NASDAQ:WGRX) reported financial results for the second fiscal quarter ending June 30, 2025. The company's revenue on a pro forma basis for the first half of 2025 stood at $18.65 million, compared to $18.25 million in the first half of 2024, reflecting a slight increase. Since its initial public offering in February 2025, Wellgistics Health has consolidated its operations, streamlined staffing, and upgraded its ERP system to support growth. The company is also expanding its direct-to-patient programs, leveraging a network of over 6,500 independent pharmacies and 200 manufacturers to enhance its reach in therapeutic areas such as diabetes, weight loss, chronic pain, sleep disorders, and men's and women's health. The CEO emphasized the company's focus on accelerating growth through strategic funding and expanding access via its direct-to-patient delivery models.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wellgistics Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1063183) on August 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"WGRX","symbol_name":"Wellgistics Health Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250820:nNDL7x0Bz9:1","article_id":"2560106443","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560106443","pubTimestamp":1755694826,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Wellgistics Health Inc.  reported financial results for the second fiscal quarter ending June 30, 2025. The company's revenue on a pro forma basis for the first half of 2025 stood at $18.65 million, compared to $18.25 million in the first half of 2024, reflecting a slight increase. Since its initial public offering in February 2025, Wellgistics Health has consolidated its operations, streamlined staffing, and upgraded its ERP system to support growth. The company is also expanding its direct-to-patient programs, leveraging a network of over 6,500 independent pharmacies and 200 manufacturers to enhance its reach in therapeutic areas such as diabetes, weight loss, chronic pain, sleep disorders, and men's and women's health. The CEO emphasized the company's focus on accelerating growth through strategic funding and expanding access via its direct-to-patient delivery models.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"WGRX":"Wellgistics Health Inc."},"translate_title":"Wellgistics Health Inc.报告2025年上半年收入为1,865万美元，较2024年上半年的1,825万美元略有增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WGRX":0.9},"content_text":"Wellgistics Health Inc. Reports $18.65 Million Revenue in H1 2025, Slight Increase from $18.25 Million in H1 2024\n    \n\n        Wellgistics Health Inc. (NASDAQ:WGRX) reported financial results for the second fiscal quarter ending June 30, 2025. The company's revenue on a pro forma basis for the first half of 2025 stood at $18.65 million, compared to $18.25 million in the first half of 2024, reflecting a slight increase. Since its initial public offering in February 2025, Wellgistics Health has consolidated its operations, streamlined staffing, and upgraded its ERP system to support growth. The company is also expanding its direct-to-patient programs, leveraging a network of over 6,500 independent pharmacies and 200 manufacturers to enhance its reach in therapeutic areas such as diabetes, weight loss, chronic pain, sleep disorders, and men's and women's health. The CEO emphasized the company's focus on accelerating growth through strategic funding and expanding access via its direct-to-patient delivery models.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wellgistics Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1063183) on August 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}